# Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

> **NCT06475235** · PHASE1 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 15 (estimated)

## Conditions studied

- Lymphoma
- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Methotrexate
- **DRUG:** Temozolomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06475235
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-18
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475235, "Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06475235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*